Sermorelin Dosing Protocol

Sermorelin acetate (also known as GRF 1-29) is one of the most widely used peptides for growth hormone optimization. It works by mimicking GHRH -- growth hormone-releasing hormone -- the natural signal your brain sends to your pituitary gland to trigger GH production. Sermorelin is a shortened version of that natural hormone: your body's GHRH is 44 amino acids long, while sermorelin uses only the first 29. Despite being shorter, this fragment retains the full ability to activate the GHRH receptor, making it a practical and effective option for stimulating your own GH production.

Because sermorelin is a close copy of natural GHRH without the structural modifications found in longer-acting alternatives like tesamorelin or CJC-1295, your body breaks it down quickly. The sermorelin half-life is approximately 11-12 minutes after subcutaneous injection, which is why it needs to be administered nightly rather than weekly. The tradeoff for this short duration is that sermorelin's effects closely mirror your body's natural GH pulse pattern.

Sermorelin was originally approved by the FDA in 1990 as a diagnostic agent for GH deficiency, and subsequently in 1997 for the treatment of idiopathic growth hormone deficiency in children, marketed under the brand name Geref by Serono Laboratories. The manufacturer voluntarily discontinued production in 2008 due to manufacturing process difficulties, not safety concerns.

Sermorelin remains available through compounding pharmacies for off-label prescribing and as a research peptide, and has gained traction in anti-aging and longevity medicine for its ability to stimulate endogenous GH production through natural pituitary pathways rather than direct exogenous GH administration.

This compound is not currently FDA-approved for any indication. All information on this page is for educational and research reference purposes only.

The table below shows how much bacteriostatic (BAC) water to add to each common sermorelin vial size and the resulting syringe volumes for typical doses. "Units" refers to the markings on a standard U-100 insulin syringe, where 100 units equals 1.0 mL.

For the cleanest measurement, the 2 mg and 5 mg vials produce round unit numbers at common doses. The 9 mg and 15 mg vials produce fractional units (for example, 3.3 units for a 100 mcg dose) -- if using these vial sizes, a syringe with half-unit markings is helpful, or you can round to the nearest whole unit for a close approximation.

Based on data from sermorelin's FDA-approved era, the peptide was generally well tolerated. Most people did not experience side effects serious enough to stop treatment.

Injection-site reactions: The most common side effect -- about 1 in 6 people (roughly 17%) experienced redness, swelling, or discomfort at the injection site. These reactions were typically mild and went away on their own. Very few people stopped treatment because of them.

Less common effects (each under 1%): Headache, facial flushing, difficulty swallowing, dizziness, restlessness, drowsiness, changes in taste, and hives were each reported rarely and generally resolved without intervention.

Antibody development: About 70% of participants in some studies developed antibodies against sermorelin (anti-GRF antibodies). This sounds alarming, but in practice these antibodies did not appear to meaningfully reduce the peptide's effectiveness in most participants. Antibody development is common with many injected peptides and is typically monitored but not a reason to discontinue.

Thyroid monitoring recommended: About 6.5% of trial participants developed hypothyroidism (underactive thyroid). Because untreated hypothyroidism can reduce your body's ability to respond to GH stimulation, baseline and follow-up thyroid blood tests were recommended in historical prescribing guidance -- and remain standard practice in current protocols.

Low abuse and dependence risk: Clinical data show no significant abuse or dependence potential with sermorelin.

Overall tolerability: Few people discontinued sermorelin due to side effects in FDA-era programs. Because sermorelin stimulates your body's own GH production through natural pathways (rather than injecting external GH), the risk of excessive GH levels is inherently lower -- your body's own feedback system acts as a safety brake.

Sermorelin has an unusual clinical background for a research peptide: it was actually FDA-approved twice -- first as a diagnostic tool in 1990, then as a treatment for childhood growth hormone deficiency in 1997. The manufacturer (Serono Laboratories) discontinued it in 2008 due to manufacturing difficulties, not safety concerns. As a result, sermorelin has real FDA-era clinical data, but most of that data involves children rather than adults. Modern adult usage relies on practitioner experience and published reviews rather than large randomized controlled trials.

Sermorelin has a unique clinical background among research peptides, including historical FDA approvals for diagnostic and pediatric GH-deficiency indications and a characterized safety profile from that period. The branded product was discontinued in 2008 for manufacturing reasons rather than safety withdrawal. Large modern adult RCT datasets remain limited after discontinuation, while off-label clinical use and practitioner-guided protocols have persisted in longevity and regenerative settings. Unlike recombinant human GH, sermorelin has historically been discussed as more flexible in off-label prescribing frameworks. No active ClinicalTrials.gov registrations for sermorelin in adult populations were identified in this guide context (February 2026).

Sermorelin, tesamorelin, and CJC-1295 (DAC) are the three main GHRH-based peptides -- they all target the same receptor in your pituitary gland, but they differ significantly in how long they last, how often you inject, and how much clinical evidence supports them. Use the table below to see how they compare, and read the decision guidance after the table for help choosing between them.

All three compounds target the GHRH receptor but differ substantially in pharmacokinetics, approval history, and modern evidence depth.

Sermorelin requires nightly dosing due to short half-life but retains extensive historical clinical context and feedback-limited pulse behavior.

Tesamorelin has stronger modern controlled evidence for visceral-fat outcomes, while CJC-1295 (DAC) emphasizes dosing convenience. For related guidance, compare with tesamorelin and CJC-1295 protocol pages before selecting a protocol model.

See the Tesamorelin protocol and CJC-1295 protocol for compound-specific guides.